The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era

  title={The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era},
  author={Sandy Liu and Gavin Hui and Colleen Mathis and Karim Chamie and Allan J. Pantuck and Alexandra Drakaki},
  journal={Clinical Genitourinary Cancer},

Figures and Tables from this paper

Resveratrol, curcumin, paclitaxel and miRNAs mediated regulation of PI3K/Akt/mTOR pathway: go four better to treat bladder cancer
The aim of this review is to discuss the interplay between PI3K/Akt/mTOR, miRNAs, and natural compounds and emphasize the importance of mi RNAs as biomarkers and resveratrol, curcumin and paclitaxel as a possible therapeutic approach against bladder cancer.
Mechanisms behind Temsirolimus Resistance Causing Reactivated Growth and Invasive Behavior of Bladder Cancer Cells In Vitro
Temsirolimus resistance is associated with reactivation of bladder cancer growth and invasive behavior and the α2, α3, and β1 integrins could be attractive treatment targets to hinder temsirolimu resistance.
Abnormal overexpression of G9a in melanoma cells promotes cancer progression via upregulation of the Notch1 signaling pathway
The data from this study demonstrates potential of G9a as a therapeutic target in the treatment of melanoma and investigates the role of UNC0642 in melanoma cells, and detected its anti-cancer effects in vitro and in vivo.
HnRNP-F promotes the proliferation of bladder cancer cells mediated by PI3K/AKT/FOXO1
Findings suggest that hnRNP-F expression is regulated by the PI3K/AKT-mediated phosphorylation of FOXO1, withosphorylation inhibiting FOXO 1, which subsequently allows hnNR NP-F to promote proliferation.
Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells
The addition of SFN to the long-term everolimus application inhibits resistance development in bladder cancer cells in vitro, and sulforaphane may hold potential for treating bladder carcinoma in patients with resistance to an mTOR inhibitor.
Knockdown of anti-silencing function 1B histone chaperone induces cell apoptosis via repressing PI3K/Akt pathway in prostate cancer
It was demonstrated that silencing of ASF1B suppressed the proliferation, and promoted apoptosis and cell cycle arrest of PCa cells, suggesting that the downregulation of ASf1B may aid in inhibiting the progression ofPCa.
Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies
Differences of the landscape of high and low TMB urothelial cancers provides leads for further pathogenesis investigations and may prove useful for development of combination therapies including immunotherapies with targeted inhibitors.
Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells
The synergistic effects of the combination therapy on the PI3K/Akt/mTOR pathway, apoptosis, and EMT were evident in Western blotting and could serve as a useful preclinical tool to evaluate various drug combinations.
Emerging biomarkers and targeted therapies in urothelial carcinoma.
Emerging biomarkers that may predict response to cisplatin-based chemotherapy, immunotherapy, emerging targeted therapies, and promising combination strategies are summarized.
Gypenoside-Induced Apoptosis via the PI3K/AKT/mTOR Signaling Pathway in Bladder Cancer
Gypenosides displayed apoptosis-inducing properties in bladder cancer cells by inactivating the PI3K/AKT/mTOR signaling pathway in vitro and inhibited the growth of bladdercancer cells in vivo.


Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors.
  • P. LoRusso
  • Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016
To maximize therapeutic benefit, drug combinations and schedules must be explored to identify those with the highest efficacy and lowest toxicity overlap, and defining appropriate patient subpopulations, for both monotherapy and drug combinations, will be important.
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
Co-existence of alterations to several PI3K pathway genes in some bladder tumours indicates that these proteins may have functions that are not related solely to the known canonical pathway.
Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer
The lack of redundancy of alterations suggests that single-agent PI3K-targeted therapy may not be successful in these cancers, and a well-characterized series of cell lines are provided for use in preclinical studies of targeted agents.
PI3K pathway alterations in cancer: variations on a theme
The high frequency of phosphoinositide 3-kinase (PI3K) pathway alterations in cancer has led to a surge in the development of PI3K inhibitors and proposed treatment strategies tailored for these genetic lesions are proposed.
GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
GDC-0980 was potent across a broad panel of cancer cell lines, with the greatest potency in breast, prostate, and lung cancers and less activity in melanoma and pancreatic cancers, consistent with KRAS and BRAF acting as resistance markers.
PI3K/AKT pathway activation in bladder carcinogenesis
It is suggested that PI3K/AKT pathway activation occurs in the entire spectrum of bladder UC regardless of stage or known most frequent molecular alterations, and independently of low PTEN expression.
The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL
For clinical development in hematological malignancies, IPI-145 is selective to CLL B cells, sparing normal B- and T-lymphocytes and BCR-activated signaling proteins AKTSer473, BADSer112, ERKThr202/Tyr204 and S6Ser235/236 are mitigated by IPi-145.
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
NVP-BEZ235 inhibits the PI3K/mTOR axis and results in antiproliferative and antitumoral activity in cancer cells with both wild-type and mutated p110-alpha, suggesting that skin may serve as surrogate tissue for pharmacodynamic studies.
Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models
Gen expression studies identified a collection of genes whose expression was associated with in vitro sensitivity to GDC-0941, and expression of a subset of these genes was found to be intimately linked to signaling through the pathway.
Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer
Results indicate that clinically relevant doses of PF-04691502 and PD-0325901 can suppress bladder tumor growth in PDX models, thus offering additional potential treatment options by a precision medicine approach.